Cell and Gene Therapy Catapult: What makes the UK one of the best places for research?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cell and Gene Therapy Catapult: What makes the UK one of the best places for research?
Released on: March 03, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Keith Thompson, CEO to Cell and Gene Therapy Catapult, describes the government’s Catapult initiative, established by Innovate UK.
  • Summary
  • Transcript
  • Participants
  • Company
Keith Thompson, CEO to Cell and Gene Therapy Catapult, describes the government’s Catapult initiative, established by Innovate UK.
Keith Thompson, CEO to Cell and Gene Therapy Catapult, describes the government’s Catapult initiative, established by Innovate UK.
Keith Thompson is Chief Executive of the Cell and Gene Therapy Catapult, an Innovate UK initiative. He has established a team of over 100 cell and gene therapy experts in new state-of-the-art laboratories in London and is now building a large-scale manufacturing centre. Keith joined the Cell and Gene Therapy Catapult from the Scottish Blood Transfusion Service where he was National Director, focussed on modernising the blood supply from vein-to-vein and expanding into cell and gene therapy. Prior to this he held various positions in Biotechnology companies. He was at various times, Managing Director of Bioscot, one of Scotland’s first Biotechnology companies, Vice President of Serologicals Diagnostics Operations, then Vice President of Global Manufacturing. He has been Chairman of the UK Blood Forum, a Director of the European Blood Alliance and Treasurer of the International Plasma Fractionators Association. He is currently a Board member of the UK BioIndustry Association and an Executive Committee member of the Alliance for Regenerative Medicine. Keith holds first and second degrees in Biological Sciences and Applied Genetics from Birmingham University along with an MBA from Edinburgh University.
Growing the UK cell and gene therapy industry, delivering health and wealth. Our vision The Cell and Gene Therapy Catapult vision is for the UK to be a global leader in the development, delivery and commercialisation of cell and gene therapy. Where businesses can start, grow and confidently develop cell and gene therapies, delivering them to patients rapidly, efficiently and effectively. Our mission Our mission is to grow the industry in the UK to substantial and sustainable levels by: taking products into clinical trial, de-risking them for further investment; providing clinical expertise and access to NHS clinical partners; providing technical expertise and infrastructure to ensure products can be made to GMP and delivered cost effectively; providing regulatory expertise to ensure that products can get to the clinic safely, in the shortest amount of time; providing opportunities for collaboration, both nationally and globally; and providing access to business expertise, grants and investment finance so that commercially viable products are progressed and investable propositions are generated.